RxDoctor Payments Data

Concettina Peloro, MD

MOHS-Micrographic Surgery · Monroe Twp, NJNPI 1174588321

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 29.0% of the total. Reporting peaked in 2022 at $164 and has fallen 57.7% since, to $70 in 2025. That places this record below the midpoint for mohs-micrographic surgery clinicians in NJ, where the typical reported total is $1,080.

$567in general payments, 2019–2025

Across 34 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$165
  • Lilly USA, LLC$89
  • AbbVie$61
  • Organogenesis Inc.$48
  • Pfizer$43
  • Incyte Corporation$31
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$567 in reported general payments places this provider in the 35th percentile of 30 mohs-micrographic surgery providers in New Jersey.

See all mohs-micrographic surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$587,943
Medicare patients
443
Services billed
2,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$54

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Monroe Twp

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →